(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -30.64% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.12%.
Aclaris Therapeutics's revenue in 2025 is $17,778,000.On average, 10 Wall Street analysts forecast ACRS's revenue for 2025 to be $645,139,622, with the lowest ACRS revenue forecast at $328,958,404, and the highest ACRS revenue forecast at $818,606,167. On average, 10 Wall Street analysts forecast ACRS's revenue for 2026 to be $607,566,032, with the lowest ACRS revenue forecast at $212,231,228, and the highest ACRS revenue forecast at $1,136,953,010.
In 2027, ACRS is forecast to generate $662,897,745 in revenue, with the lowest revenue forecast at $424,462,457 and the highest revenue forecast at $808,102,887.